- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03672240
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC)
A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- The Icahn School of Medicine at Mt. Sinai
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Carolina Urologic Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subject Eligibility Criteria:
Inclusion Criteria:
History of Intermediate Risk or High Risk Transitional Cell Carcinoma Non-Muscle Invasive Bladder Cancer as defined by AUA Guidelines:
AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer
Low Risk LGa solitary Ta ≤ 3cm PUNLMPb
Intermediate Risk Recurrence within 1 year Solitary LG Ta > 3cm LG Ta, multifocal HGc Ta, ≤ 3cm LG T1
High Risk HG T1 Any recurrent, HG Ta HG Ta, >3cm (or multifocal) Any CISd Any BCG failure in HG patient Any variant histology Any LVIe Any HG prostatic urethral
a. LG = low grade; b. PUNLMP = papillary urothelial neoplasm of low malignant potential; c. HG = high grade; d. CIS=carcinoma in situ; e. LVI = lymphovascular invasion.
- History of prior induction course of intravesical BCG, using 1/3 to full dose of BCG for 6 treatments (BCG Naïve will not be eligible). Previous BCG treatment in combination with interferon is allowed.
- Patients who are eligible will either receive maintenance course (3 treatments 1/3 to full dose) or repeat induction course (6 treatments 1/3 to full dose)
- Principal Investigator's discretion if patients who have a negative cystoscopy or urine cytology following initial BCG induction, can be placed on maintenance BCG to recurrence of bladder cancer
- 18 years of age or older
- Eastern Cooperative Oncology Group (ECOG) performance status < 2
- Not pregnant or lactating
- Subjects with child bearing or fathering potential must agree to use adequate contraception during the study and for 3 months after last treatment of investigational drug
- Agree to study specific informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
- Adequate baseline complete blood count (CBC), renal and hepatic function:
1) Parameters described as WBC > 3000 cells/mm3, ANC > 1,000 cells/mm3, hemoglobin > 8.5 g/dL, and platelet count >100,000 cells/mm3 2) Adequate renal function: serum creatinine < 1.5 x upper limit of normal (ULN) 3) Bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are not more than 2 x Upper Limits of Normal 4) Absolute lymphocyte count ≥ 800/μL before the first dose of APL-1202
Exclusion Criteria:
- Stage T2 or above urothelial carcinoma or urothelial carcinoma outside the bladder
- Stage T1 NMIBC recurred at 3 months or shorter from the first dose of prior induction BCG course
- Recurrent high-grade Ta/T1 disease within 6 months from the last dose of adequate BCG therapy
- Previous systemic immunotherapy for bladder cancer
- Prior major surgery (not Transurethral Resection of Bladder Tumor [TURBT/Cystoscopy]), radiation therapy, or systemic therapy within 8 weeks of starting the study treatment
- National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 hemorrhage within four weeks from the starting study treatment
- Any of the following medical conditions within the six months prior to investigational drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
- Hypertension that cannot be controlled by medications
- Optic nerve disorders or with a history of optic nerve disorders
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or investigational drug administration, or may interfere with the interpretation of study results in the judgment of the Investigator
- Clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation components in the investigational drug
- Systemic treatment on any investigational clinical trial within 28 days (or 5 half-lives of that agent, whichever is greater) prior to enrollment
- Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose nonsteroidal anti-inflammatory drugs (NSAIDs), are permitted). Use of a short course (i.e., ≤ 2 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for: computed tomography (CT) scans
- Immunosuppressive therapy, including: cyclosporine, anti-thymocyte globulin, or tacrolimus within three months of study entry
- Concurrent treatment with strong inducers or inhibitors of CYP450 enzymes
- Concurrent treatment with low therapeutic index drugs (such as methotrexate) that are renally cleared by OAT1- and OAT3-mediated transport
- History of prior malignancy, except for adequately treated in situ cancer or basal cell or squamous cell skin cancer or other cancers (e.g. breast, prostate) for which the patient has been disease free and/or received curative therapy. Exclusion of patients described above will be at the discretion of the Sponsor.
- Progressive or persistent viral or bacterial infection
- All infections must be resolved, and the subject must remain afebrile for seven days without antibiotics prior to enrollment
- Urinary tract infection, including particularly bladder infection, must be resolved prior to being placed on study
- Unmanageable active gastric ulcer or inflammation of gastrointestinal (GI) tract
- Gastric bleeding within last 6 months prior to enrollment
- Anuria
- Unable to take oral medication
- Unwilling or unable to comply with the protocol or cooperate fully with the Investigator and site personnel
- Unwilling to sign the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: APL-1202
|
To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and Severity of Treatment-Related Adverse Events
Time Frame: 13 weeks
|
Incidence and Severity of Treatment-Related Adverse Events as Assessed by CTCAE v.5.0 or newer
|
13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics - Area Under Curve
Time Frame: On Week 2 prior to first BCG instillation
|
PK measurement expressed as area under curve for APL-1202
|
On Week 2 prior to first BCG instillation
|
Pharmacokinetics - Area Under Curve
Time Frame: On Week 6 prior to fifth BCG instillation
|
PK measurement expressed as area under curve for APL-1202
|
On Week 6 prior to fifth BCG instillation
|
Pharmacokinetics - Maximum Plasma Concentration
Time Frame: On Week 2 prior to first BCG instillation
|
PK measurement expressed as maximum plasma concentration for APL-1202
|
On Week 2 prior to first BCG instillation
|
Pharmacokinetics - Maximum Plasma Concentration
Time Frame: On Week 6 prior to fifth BCG instillation
|
PK measurement expressed as maximum plasma concentration for APL-1202
|
On Week 6 prior to fifth BCG instillation
|
Pharmacokinetics - Half-Life
Time Frame: On Week 2 prior to first BCG instillation
|
PK measurement expressed as half-life for APL-1202
|
On Week 2 prior to first BCG instillation
|
Pharmacokinetics - Half-Life
Time Frame: On Week 6 prior to fifth BCG instillation
|
PK measurement expressed as half-life for APL-1202
|
On Week 6 prior to fifth BCG instillation
|
Pharmacokinetics - Cumulative Amount in Urinary Excretion
Time Frame: Eight hours after first dose on Week 2 prior to first BCG instillation
|
PK measurement expressed as cumulative amount in urinary excretion for APL-1202
|
Eight hours after first dose on Week 2 prior to first BCG instillation
|
Pharmacokinetics - Cumulative Amount in Urinary Excretion
Time Frame: Eight hours after first dose on Week 6 prior to fifth BCG instillation
|
PK measurement expressed as cumulative amount in urinary excretion for APL-1202
|
Eight hours after first dose on Week 6 prior to fifth BCG instillation
|
Pharmacokinetics - Cumulative Fraction of Dose in Urinary Excretion
Time Frame: Eight hours after first dose on Week 2 prior to first BCG instillation
|
PK measurement expressed as cumulative fraction of dose in urinary excretion for APL-1202
|
Eight hours after first dose on Week 2 prior to first BCG instillation
|
Pharmacokinetics - Cumulative Fraction of Dose in Urinary Excretion
Time Frame: Eight hours after first dose on Week 6 prior to fifth BCG instillation
|
PK measurement expressed as cumulative fraction of dose in urinary excretion for APL-1202
|
Eight hours after first dose on Week 6 prior to fifth BCG instillation
|
Collaborators and Investigators
Investigators
- Study Chair: Harish Dave, MD, Linical Accelovance
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- YHGT-NB-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Muscle Invasive Bladder Cancer (NMIBC)
-
Prokarium LtdRecruitingA Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBCUnited States
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Muscle Invasive Bladder Cancer (NMIBC)United States
-
Ractigen Therapeutics.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)Australia
-
Fidia Farmaceutici s.p.a.TerminatedNon-muscle Invasive Bladder Cancer (NMIBC)Italy
-
Anchiano Therapeutics Israel Ltd.TerminatedNon-muscle Invasive Bladder Cancer (NMIBC)United States
-
VitadxFONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTERecruitingNon-muscle Invasive Bladder Cancer (NMIBC)France, Belgium, Spain
-
Aadi Bioscience, Inc.National Cancer Institute (NCI)CompletedNon-muscle Invasive Bladder Cancer (NMIBC)United States
-
University of OxfordMerck Sharp & Dohme LLCTerminatedNon-muscle Invasive Bladder Cancer (NMIBC)United Kingdom
-
Case Comprehensive Cancer CenterWithdrawnNon-muscle Invasive Bladder Cancer (NMIBC) | Bladder Tumor (TURBT)United States
Clinical Trials on APL-1202
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisNot yet recruiting
-
Asieris Pharmaceuticals (AUS) Pty Ltd.Completed
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisCompleted
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingMuscle Invasive Bladder CancerUnited States, China
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruiting
-
CerecinCompleted
-
CerecinCompleted
-
Apellis Pharmaceuticals, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States, Australia
-
TG Therapeutics, Inc.TerminatedChronic Lymphocytic Leukemia | Non Hodgkin LymphomaUnited States
-
TG Therapeutics, Inc.SCRI Development Innovations, LLCCompletedHodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Peripheral T-Cell LymphomaUnited States